Abstract: The accurate diagnosis of interstitial lung disease is essential for optimal prognostication and management. Although connective tissue disease is among the most common causes of interstitial lung disease, some patients have features suggestive of autoimmunity without meeting criteria for a specific connective tissue disease. To help define and study this disease entity more uniformly, a 2015 research statement proposed consensus-based criteria and coined the term "interstitial pneumonia with autoimmune features" (IPAF). In this review, we summarize and compare previously proposed criteria to characterize these patients, provide an overview of the IPAF criteria, and highlight recent investigations aimed at characterizing IPAF cohorts. Thereafter, we call attention to questions that have arisen with the application of the IPAF criteria and discuss future areas of study.
I
nterstitial lung disease (ILD) is composed of a heterogenous group of diffuse parenchymal lung processes and accounts for about 15% of conditions seen in general pulmonary practice. 1 Among the most common ILDs are connective tissue diseaseassociated ILD (CTD-ILD) and idiopathic pulmonary fibrosis (IPF). Because CTD-ILD generally follows a favorable clinical course compared with IPF, and because therapies differ substantially between the 2 processes, an accurate diagnosis is critical. 2, 3 All patients undergoing ILD evaluation should undergo high-resolution computed tomography (HRCT), surgical lung biopsy (SLB) when indicated, and multidisciplinary discussion between clinicians, a radiologist, and pathologist (when needed) with ILD expertise. 4 Consultation with a rheumatologist should also be considered for patients with suspected CTD-ILD.
Up to 30% of newly diagnosed ILD will be due to CTD. 5, 6 Although most patients will manifest a radiographic and/or histopathologic pattern of nonspecific interstitial pneumonia (NSIP), 7, 8 a substantial minority will manifest usual interstitial pneumonia (UIP), which is diagnostic of IPF in the absence of other known causes of ILD. 9 Despite a similar pattern as those with IPF, those with CTD-associated UIP generally experience better outcomes, [10] [11] [12] underscoring the importance of assessing all patients with ILD, including those with UIP, for occult CTD. Although some patients will develop ILD several months to years before other CTD features, others will have signs or symptoms suggestive of a CTD without meeting specific CTD criteria. Because these patients may represent a unique phenotype, several classification systems have been proposed in recent years. [13] [14] [15] [16] [17] [18] The need for a standardized classification system and improved understanding of this patient population led to the formation of the European Respiratory Society (ERS)/American Thoracic Society (ATS) Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease. This group produced an official ERS/ATS research statement proposing criteria for patients with "interstitial pneumonia with autoimmune features" (IPAF). 19 In this article, we provide historical context for the emergence of IPAF criteria, outline specific features comprising the IPAF criteria, review several recently characterized IPAF cohorts, highlight unanswered questions that have arisen with the application of these criteria, and discuss areas needing further study.
PREINTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES CLASSIFICATION
In the 15 years before the release of the IPAF criteria, several unique, yet overlapping classification systems were proposed to help characterize patients with features of autoimmunity who failed to meet overt CTD definitions. Among the first investigations to call attention to this disease entity were those that focused on NSIP, a radiographic and pathologic pattern commonly encountered in CTD-ILD. 6 The strong link between NSIP and CTD, along with high frequency of circulating autoantibodies in patients with NSIP, led investigators to hypothesize that idiopathic NSIP represented an "autoimmune interstitial pneumonia" 13 or "undifferentiated connective tissue disease" (UCTD). 14 Kinder et al 14 and colleagues proposed formal criteria for UCTD, which required at least 1 symptom and 1 circulating autoantibody suggestive of CTD. Those meeting the proposed UCTD criteria were more likely to have SLB-proven NSIP, supporting the hypothesis that NSIP was an autoimmune phenomenon and that UCTD-ILD was a pulmonary manifestation of CTD. Because UCTD, as defined by rheumatologists, describes patients with a milder disease course that is not frequently complicated by ILD, 20 Fischer et al 17 suggested that "lung-dominant" CTD (LD-CTD) was more appropriate nomenclature. Criteria for LD-CTD included the combination of ILD, failure to meet definitive criteria for a CTD, no alternative etiology for ILD, and 1 autoantibody or 2 histopathologic features suggestive of CTD.
Corte et al 15 refined the UCTD criteria proposed by Kinder and colleagues by developing an algorithm to predict the presence of NSIP on SLB using clinical and serologic features suggestive of CTD. Compared with the broader UCTD criteria proposed by Kinder and colleagues, those proposed by Corte had a higher specificity for predicting biopsy-proven NSIP. A similar classification system was proposed by Vij et al, 16 who suggested the term "autoimmune-featured interstitial lung disease" (AIF-ILD) to describe this patient population. As opposed to the UCTD cohort with NSIP characterized by Corte and colleagues, UIP predominated in the AIF-ILD cohort characterized by Vij and colleagues. Despite these differences, survival was similar between patients meeting the UCTD/AIF-ILD criteria and those with IPF at each center.
Given the multiple proposed classification schemes for relatively similar cohorts, Assayag et al 18 compared each set of criteria (Kinder, Corte, Fischer, Vij) to better characterize these overlapping groups. These investigators found that all 4 sets of criteria described a similar group of patients, but that more patients met the Fischer and Kinder criteria as compared with the Vij and Corte criteria. This analysis also suggested that meeting each set of criteria was associated with better survival compared with patients with chronic fibrosing interstitial pneumonia who did not meet the criteria, although only the Corte criteria remained an independent predictor of survival after adjusting for the gender-age-physiology (GAP) score. 21 
INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES RESEARCH STATEMENT: THE CRITERIA
The need for consensus when studying this patient population resulted in the 2015 publication of the joint ERS/ATS research statement, coining the term IPAF. 19 The IPAF criteria (Table 1) 
Clinical Domain
Clinical features most strongly associated with specific CTDs based on the task force consensus opinion are included in this domain. These include distal digital fissuring (mechanic's hands), digital tip ulceration, inflammatory arthritis, or polyarticular morning stiffness lasting over 60 minutes, palmar telangiectasia, Raynaud phenomenon, unexplained digital edema, and unexplained fixed rash on the digital extensor surfaces (Gottron sign). The task force aimed to include signs and symptoms specific for autoimmune etiologies but whose absence does not rule out the presence of a CTD. Clinical findings included in the previously proposed criteria, including alopecia, dysphagia, photosensitivity, oral ulcers, weight loss, sicca symptoms, myalgia, arthralgia, and proximal muscle weakness, were not included, as they were felt to be insufficiently specific for CTD.
Serologic Domain
The task force again emphasized specificity in this domain by selecting autoantibodies with strong CTD association and by requiring moderately elevated titers for less specific autoantibodies, such as antinuclear antibody (ANA) and rheumatoid factor (RF). To satisfy the IPAF serologic domain with an ANA or RF, patients must have ANA ≥ 1:320 (or nucleolar or centromere pattern at any titer) or RF at ≥ 2 times the upper limit of normal. Antineutrophil cytoplasmic antibody is not included in the IPAF criteria, as this is associated with vasculitis-associated ILD rather than ILD due to CTD.
Morphologic Domain
The morphologic domain is separated into 3 subdomains: radiographic, pathologic, and multicompartment. The radiographic and pathologic subdomains focus on HRCT and SLB features associated with CTD, and were largely in line with those proposed by Fischer and colleagues as part of the LD-CTD criteria. HRCT features include NSIP, organizing pneumonia (OP), NSIP with OP overlap, and lymphocytic interstitial pneumonia (LIP) (Fig. 1) . Although NSIP is the most common HRCT pattern observed in CTD-ILD, OP is also common and LIP is strongly correlated with Reproduced with permission of the European Respiratory Society (Fischer et al) . 19 Sjogren disease. 22 Although the UIP pattern can be seen in the setting of CTD, particularly rheumatoid arthritis (RA), it is not included in the IPAF criteria given the lack of specificity. Similar to the radiographic subdomain, the pathologic subdomain includes NSIP, OP, NSIP with OP and LIP. Like HRCT, NSIP is also the most commonly encountered SLB pattern observed in CTD-ILD. 7, 8 Interstitial lymphoid aggregates with germinal centers and diffuse lymphoplasmacytic infiltration were also included in the pathologic subdomain, given their strong association with CTD. 10 Although pathologic UIP is commonly observed in patients with RA and systemic sclerosis (SSc), 23, 24 this finding was not included in the pathologic subdomain because of the lack of specificity.
Recognition that CTD often results in extraparenchymal thoracic manifestations also led to the inclusion of a multicompartment subdomain. Such manifestations include unexplained pleural or pericardial effusion or thickening, intrinsic airways disease (defined as airflow obstruction, bronchiolitis, or nontraction bronchiectasis), and pulmonary vasculopathy. Unexplained pleural or pericardial effusion or thickening on HRCT has been shown to occur more frequently with CTD-ILD than idiopathic interstitial pneumonia. 25 Concomitant airway disease is often present in patients with CTD, particularly RA, 26 and features such as a disproportionately reduced forced expiratory volume in 1 second or elevated residual volume on pulmonary function test, mosaic attenuation or bronchiectasis on HRCT, or follicular or constrictive bronchiolitis on SLB could be used to make this determination. 19 Precapillary pulmonary hypertension is a prevalent clinical manifestation in CTDs, particularly scleroderma, 27 and is defined as a mean pulmonary artery pressure of over 25 mm Hg in the setting of a pulmonary arterial wedge pressure of <15 mm. 28 Although right heart catheterization is necessary before initiating therapy in these patients, echocardiography may serve as an effective screening tool. 29 
APPLICATION OF INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES CRITERIA TO INTERSTITIAL LUNG DISEASE COHORTS
Several groups have applied the IPAF criteria to ILD cohorts in recent years. These studies, which include centers from North America and Europe, demonstrated substantial heterogeneity between cohorts with regard to phenotype and outcomes.
Prevalence and Distribution of Features
The true prevalence of IPAF is difficult to ascertain given the variability in how criteria are applied and the patient populations in which they are measured. Our group retrospectively applied the IPAF criteria to all patients with IIP and UCTD-ILD (by Corte criteria) followed at our center (n = 422) and identified 144 patients (34%) who met the inclusion criteria. 30 These patients were predominantly white, had a mean age of 63 years, had a slight (52%) female predominance, and over half (55%) endorsed a history of smoking. Similar to prior findings by Ferri et al, 31 the most common clinical feature in our cohort was the Raynaud phenomenon (28%) and the most common serologic feature was ANA seropositivity (76%). When assessing morphologic features, NSIP was the most common pattern observed on HRCT (32%) and SLB (23%). Despite these morphologic features, the majority of patients in this cohort had UIP on either HRCT or SLB. Most patients (51%) met the IPAF criteria through a combination of serologic and morphologic domains, and only 26% met all 3 domains.
Chartrand et al 32 characterized a cohort of 56 patients meeting the IPAF criteria with substantially lower UIP prevalence. These patients were younger (mean age, 55) and were predominantly white women. Raynaud phenomenon (39%) and ANA seropositivity (48%) were again the most commonly observed clinical and serologic features, respectively. Morphologically, a majority of patients had NSIP on HRCT (52%) or SLB (33%), and only 9% of patients had UIP. As compared with our cohort, over half of the patients manifested a feature in all 3 domains.
A European IPAF cohort was characterized by Ahmad et al, 33 who screened 778 patients and identified 57 (7.3%) meeting criteria. Similar to our cohort, these patients had a mean age of 64 and relatively even sex distribution. Raynaud phenomenon was again the most common clinical feature (74%), ANA seropositivity the most common serologic feature (82%), and NSIP the most common feature on HRCT (53%). Few patients in this cohort underwent SLB. FIGURE 1. Kaplan-Meier survival curves of IPAF, IPF, and CTD-ILD cohorts. Overall (A) IPAF cohort survival was significantly worse than the CTD-ILD cohort (P < 0.001) and marginally better than the IPF cohort (P = 0.07). After stratification of the IPAF cohort by the presence of a UIP pattern on high-resolution computed tomography and/or surgical lung biopsy (B), IPAF patients without UIP demonstrated survival similar to those with CTD-ILD (P = 0.45), whereas those with UIP demonstrate survival similar to those with IPF (P = 0.51). CTD indicates connective tissue disease; ILD, interstitial lung disease; IPAF, interstitial pneumonia with autoimmune features; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia. Reproduced with permission of the European Respiratory Society (Oldham et al) . 30 
Outcomes
The outcome data for the presently characterized IPAF cohorts also demonstrate variability. Our group described significantly worse survival in those meeting the IPAF criteria when compared with a CTD-ILD cohort and only marginally better survival compared with an IPF cohort (Fig. 1A) . 30 After stratifying the cohort on the basis of the presence of UIP on HRCT and/or SLB, IPAF patients without UIP had similar survival as a CTD-ILD cohort, whereas those with UIP had similar survival as an IPF cohort (Fig. 2B) . In exploratory analysis, satisfying the clinical domain was associated with improved survival, whereas satisfying the serologic and morphologic domains was not. Within the morphologic domain, satisfying HRCT criteria was associated with improved survival, whereas satisfying the multicompartment domain was associated with worse survival. This discordance likely arose from the large number of patients with IPF who met the IPAF criteria through fulfillment of the serologic domain and multicompartment subdomain.
Chartrand et al 32 did not observe any deaths during the 5-year follow-up period of their study. This discordance in survival may stem from the vastly different prevalence of UIP between studies. However, despite a higher prevalence of NSIP in their study, Ahmad et al 33 demonstrated similar survival patterns between their IPAF and IPF cohorts. Another possible explanation for the differences in outcome between IPAF cohorts lies in the high percentage of patients with a positive tRNA synthetase antibody in the Chartrand study, which may correlate with a more inflammatory-predominant ILD responsive to immunosuppression (discussed further below).
When assessing changes in longitudinal pulmonary function, Chartrand and colleagues showed that most patients meeting the IPAF criteria experienced stability in forced vital capacity over time. These authors noted that all but 1 patient was treated with immunosuppression, which included systemic corticosteroids and often a steroid-sparing agent such as mycophenolate mofetil or azathioprine. 32 Collins et al 34 also showed that patients meeting the IPAF criteria demonstrated stability in pulmonary function over a 1-year follow-up period, but similar trends were observed in CTD-ILD and lone IPF cohorts during this time.
Additional predictors of mortality in those meeting the IPAF criteria have been described. Ahmad et al 33 showed history of smoking cigarettes to be an independent predictor of mortality in their cohort. Chung et al 35 recently showed the presence of mosaic attenuation on HRCT to be associated with worse survival in IPAF. These investigators also showed that increased PA diameter, which may predict the presence of pulmonary hypertension, 36 was also associated with worse survival.
UNANSWERED QUESTIONS
Since the publication of the consensus statement, several important questions have arisen with regard to each of the IPAF domains. Features composing the clinical domain were chosen with specificity in mind and were fewer than previously proposed clinical criteria for UCTD, AIF-ILD, and LD-CTD. Two features excluded from the IPAF clinical domain were dysphagia and myopathy. Esophageal dysfunction complicates many CTDs and is suggested by symptomatic gastroesophageal reflux, dysphagia, eating-associated aspiration, esophageal dilation on HRCT, or abnormal esophageal motility on functional testing. This feature is especially prevalent in scleroderma-spectrum CTD. 37 Although gastroesophageal reflux is nonspecific and commonly encountered in patients with IPF, 38 some have suggested that esophageal dysmotility may be more specific for CTD and should be reconsidered in subsequent IPAF criteria iterations. 39, 40 Similarly, because proximal muscle weakness and myalgia are among the most common clinical manifestations in patients with polymyositis and dermatomyositis as a whole, 41 some have advocated for inclusion of these features in the IPAF clinical domain. 39 A question surrounding the serologic domain has stemmed from whether patients meeting IPAF criteria by the presence of a circulating tRNA synthetase antibody, and additional features within the clinical or morphologic domain, should instead be characterized as having the antisynthetase syndrome. 42 Although Connors et al 43 suggested that the presence of a circulating tRNA synthetase antibody in the setting of ILD is sufficient to diagnose the antisynthetase syndrome, Solomon et al 44 proposed that inflammatory arthritis, Raynaud, or mechanics hands (at least 2 of 3) be present in such patients without overt polymyositis/ dermatomyositis to meet criteria for antisynthetase syndrome. Mejia et al 45 recently demonstrated that all patients with ILD and a circulating tRNA synthetase antibody who failed to meet the criteria for dermatomyositis subsequently met the IPAF criteria and that survival was similar between the 2 groups. Over one third of patients included in the IPAF cohort characterized by Chartrand and colleagues had a positive tRNA synthetase antibody, which, given the proclivity of this group to respond to immunosuppression, [46] [47] [48] may explain the low mortality in this group compared with other IPAF cohorts.
Multiple questions have arisen in the application of the morphologic domain. Although UIP is not a feature that satisfies the HRCT or SLB subdomains, it remains unclear how patients with IPAF-SLB features should be characterized in the setting of background UIP. A recent investigation by Adegunsoye et al 49 found that a large minority of cases with UIP have another pathologic feature that satisfies the IPAF pathologic subdomain. Because survival is typically better among patients with UIP due to CTD compared with patients with IPF, 11, 12 it may be reasonable for patients with UIP and concurrent NSIP, OP, lymphoid aggregates with germinal centers, or diffuse lymphoplasmacytic infiltrate to satisfy the IPAF-SLB subdomain.
Another issue with the morphologic domain stems from the requirement that a feature within the multicompartment subdomain be "not otherwise explained." Because a history of smoking cigarettes can lead to intrinsic airways disease vis-à-vis emphysema-mediated obstruction, such history may explain these findings when present. In addition, because World Health Organization group III pulmonary hypertension can complicate chronic lung disease, it remains unclear when to consider the presence of pulmonary vasculopathy to be not otherwise explained. Some have also pointed out that there exists considerable uncertainty at which point, and by which measure, intrinsic airways disease and pulmonary vasculopathy are considered sufficiently present to justify a multicompartment designation. 50 
FUTURE DIRECTIONS
As an increasing number of IPAF cohorts are characterized, it will be important to begin validating individual domains, and features within domains, as they relate to clinically relevant endpoints. Because IPAF seeks to identify patients with occult CTD, one relevant endpoint will be the percentage of patients meeting the IPAF criteria who go on to develop overt CTD. Two single-center studies suggested that 10% of patients with UIP and 17% of patients with NSIP on SLB ultimately developed a CTD. 51, 52 This contrasts the findings by Chartrand et al, 32 who showed that no patients in their IPAF cohort developed CTD during a 5-year follow-up period. Validating individual IPAF criteria against outcomes will also be important, as the identification of specific features predictive of differential survival will assist in risk stratification.
The response to therapy by patients meeting the IPAF criteria will be another critical area of study. Substantial variability existed between the recently characterized IPAF cohorts with respect to immunosuppressive use. Whether this influenced survival differences between the IPAF cohorts, or whether it merely reflected phenotypic differences in these cohorts, remains unclear. In addition, because data suggest that the IPAF criteria may characterize a highly heterogenous phenotype, some patients may be more appropriately treated with antifibrotic therapy, specifically those who would otherwise be diagnosed with IPF.
CONCLUSIONS
The IPAF criteria represent an important step forward in the classification of patients with ILD and features of autoimmunity who fail to meet overt CTD criteria. It must be stressed that this guideline is a research statement based on expert consensus, rather than a validated classification system. Substantial work lies ahead to begin validating these criteria, determining how they inform clinical decision-making, and identifying IPAF subgroups most appropriate for ILD-specific therapies.
